Preliminary assessment of serum clusterin as a potential biomarker for canine lymphoma

McNaught, K. A., Morris, J. S. and McLaughlin, M. (2020) Preliminary assessment of serum clusterin as a potential biomarker for canine lymphoma. Veterinary and Comparative Oncology, 18(3), pp. 292-302. (doi: 10.1111/vco.12550) (PMID:31654603)

[img] Text
204308.pdf - Accepted Version

1MB

Abstract

Clusterin (CLU), also known as apolipoprotein J, is a widely expressed, heterodimeric, glycoprotein, important in tumourigenesis, apoptosis and immunoregulation. In humans, CLU expression has been associated with anaplastic large cell and Hodgkin's lymphoma. In this study, serum CLU levels in dogs with multicentric lymphoma (MLSA) were compared with healthy control dogs, using both western blot and enzyme‐linked immunosorbent assay (ELISA). Western blot confirmed the presence of CLU in dog sera at the predicted molecular weight and the relative levels detected correlated with the levels detected by ELISA. CLU level analysis by ELISA found treatment naïve dogs with MLSA had a significantly (P < .001) lower serum CLU level compared with healthy controls. However, there was no significant difference between MLSA dogs prior to treatment and in complete remission. The wide variation in serum CLU levels may limit its potential as a single candidate biomarker for MLSA, although any prognostic predictive value of serum CLU concentrations has yet to be assessed.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McLaughlin, Dr Mark and Morris, Professor Joanna and McNaught, Dr Katie
Authors: McNaught, K. A., Morris, J. S., and McLaughlin, M.
College/School:College of Medical Veterinary and Life Sciences > School of Biodiversity, One Health & Veterinary Medicine
Journal Name:Veterinary and Comparative Oncology
Publisher:Wiley
ISSN:1476-5810
ISSN (Online):1476-5829
Published Online:26 October 2019
Copyright Holders:Copyright © 2019 John Wiley & Sons Ltd
First Published:First published in Veterinary and Comparative Oncology 18(3): 292-302
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record